ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1399	National Cancer Institute	Html	en	Nausea and Vomiting Related to Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about nausea and vomiting as complications of cancer or its treatment. Approaches to the management of nausea and vomiting are discussed.	cancer treatment 0.379171 chemotherapy session 0.416704 past chemotherapy treatments 0.404595 motion sickness 0.3776 chemotherapy 0.552867 PDQ cancer information 0.463652 chemotherapy treatment 0.441369 late nausea 0.506038 anticipatory nausea 0.711385 clinical trials 0.378644 vomiting 0.900093 Vomiting Related 0.471509 cancer information summary 0.41736 patients 0.393418 earlier chemotherapy session 0.400031 treatment room 0.360635 NCI’s PDQ 0.353745 nausea 0.98576 NCI PDQ cancer 0.3835 radiation therapy 0.495467 antinausea drugs 0.406187 involuntary body functions 0.353798 certain chemotherapy drugs 0.416814 following treatment factors 0.366128	radiation therapy treatments 0.356798 treatment 0.558325 gastrointestinal tract 0.416866 following table 0.366172 delayed nausea 0.530808 Cancer Information Service 0.360675 following patient factors 0.352013 previous chemotherapy sessions 0.394908 patient 0.370352 treatment clinical trials 0.357831 National Cancer Institute 0.420163 Palliative Care Editorial 0.381728 new treatment 0.358991 chronic nausea 0.490418 drugs 0.426328 Cancer Care page 0.352418 Care Editorial Board 0.382615 chemotherapy sessions 0.400414 PDQ summary 0.40058 Nausea section 0.481663 cancer information summaries 0.360345 comprehensive cancer information 0.360198 cancer therapy 0.357442 acute nausea 0.484601	CLICK HERE
1546	National Cancer Institute	Html	en	AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of AIDS-Related Lymphoma.	cancer treatment 0.383886 AIDS-Related Lymphoma Treatment 0.393286 cancer spreads 0.326687 malignant tumor cells 0.309541 body 0.433918 chemotherapy 0.309155 PDQ cancer information 0.394743 clinical trial search 0.3032 white blood cells 0.3776 clinical trials 0.731846 cancer information summary 0.354741 clinical trial 0.454136 AIDS-related peripheral/systemic lymphoma 0.466219 patients 0.380662 blood cells 0.399358 old blood cells 0.295369 AIDS-related lymphomas 0.315773 treatment clinical trial 0.296684 NCI PDQ cancer 0.309251 lymph nodes 0.464743 large B-cell lymphoma 0.331734 radiation therapy 0.344733 Treatment Editorial Board 0.312981 lymph node groups 0.478813 treatment 0.574951	swollen lymph nodes 0.339153 cancer cells 0.476016 lymph node group 0.321747 specific cancer cells 0.306685 AIDS-related non-Hodgkin lymphoma 0.392687 primary cns lymphoma 0.430113 treatment clinical trials 0.33124 National Cancer Institute 0.355357 aids-related lymphoma 0.927549 lymph vessels 0.351707 new treatment 0.337577 External radiation therapy 0.327164 B-cell immunoblastic lymphoma 0.332379 AIDS-related primary CNS 0.358458 bone marrow 0.523968 cancer clinical trials 0.341952 stage 0.313358 treatment options 0.307053 nervous system lymphoma 0.295273 cancer 0.766753 standard treatment 0.309541 lymph tissue 0.333823 body lymphoma 0.323497 Burkitt-like lymphoma 0.311372	CLICK HERE
1585	National Cancer Institute	Html	en	Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version	Multiple myeloma, plasmacytoma, lymphoplasmacytic lymphoma, and monoclonal gammopathy of undetermined significance (MGUS) are different types of plasma cell neoplasms. Find out about risk factors, symptoms, tests to diagnose, prognosis, stages, and treatment for these diseases.	red blood cells 0.474629 myeloma cells 0.443938 cancer treatment 0.407402 Myeloma treatment options 0.373753 biologic therapy 0.382101 blood -forming cells 0.372128 body 0.40943 type 0.393577 PDQ cancer information 0.415525 bone marrow aspiration 0.378402 clinical trial search 0.419003 white blood cells 0.422631 clinical trials 0.689828 mature blood cells 0.378353 abnormal plasma cells 0.479263 cancer information summary 0.39289 clinical trial 0.492432 stem cells 0.378 multiple myeloma 0.975001 patients 0.39195 blood cells 0.516713 plasma cell neoplasm 0.43097 radiation therapy 0.450659 Treatment Editorial Board 0.365249 General information 0.366352	treatment 0.57038 skeletal bone survey 0.42368 immature blood cells 0.371472 plasma cell tumor 0.384236 NCI-supported cancer 0.3737 cancer cells 0.440163 normal blood cells 0.369334 specific cancer cells 0.38023 diagnose multiple myeloma 0.381187 patient 0.372697 treatment clinical trials 0.388849 National Cancer Institute 0.392841 initial treatment 0.372799 new treatment 0.406543 plasma cells 0.480204 refractory multiple myeloma 0.365057 bone marrow 0.582695 healthy blood cells 0.378266 cells 0.557939 cancer clinical trials 0.42623 cancer 0.627272 information 0.418087 myeloma cells increases 0.397071 plasma cell neoplasms 0.895903	CLICK HERE
1638	National Cancer Institute	Html	en	Essiac/Flor Essence (PDQ®)–Patient Version	Essiac and Flor Essence are herbal tea mixtures first developed in Canada that are thought to remove toxins and poisons from the body and strengthen the immune system, although this has not been proven in cancer patients. Read about the history of Essiac and Flor Essence, the theory behind its use, and the results of laboratory, animal, and human studies.	Essiac formula 0.502569 peer-reviewed scientific journals 0.490423 cancer treatment 0.454247 cancer prevention 0.375568 Complementary Therapies Editorial 0.416551 Kill cancer cells 0.376017 breast cancer patient 0.382628 Drug Administration 0.400504 Cancer Information Specialist 0.387931 Flor Essence 0.977313 Flor Essence state 0.48205 herbal dietary supplements 0.446297 Flor Essence formulas 0.482148 Cancer Information Service 0.448298 Essiac 0.851494 Essiac herbal teas 0.514938 PDQ cancer information 0.515287 health tonics 0.425459 Cancer Complementary 0.397385 Flor Essence products 0.478002 CAM therapies 0.376991 prostate cancer cells 0.376887 Flor Essence tea 0.479505 National Cancer Institute 0.598699	studies 0.410222 Sloan-Kettering Cancer Center 0.381887 clinical trials 0.491591 Royal Cancer Commission 0.384396 alternative medicine 0.441037 health care 0.376403 cancer information summary 0.466243 alternative cancer therapies 0.394811 Federal Trade Commission 0.379856 clinical trial 0.417042 cancer cells 0.389663 Essiac/Flor Essence 0.431725 CAM cancer research 0.383472 herbal tea mixtures 0.394707 cancer patients 0.424798 NCI PDQ cancer 0.416273 cancer information database 0.392781 effects 0.382227 alternative therapies 0.415163 cancer information summaries 0.394001 Therapies Editorial Board 0.400185 cancer 0.660273 research studies 0.398662	CLICK HERE
1644	National Cancer Institute	Html	en	Gerson Therapy (PDQ®)–Patient Version	Expert-reviewed information summary about the use of the Gerson therapy as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	treatment 0.476929 cancer treatment 0.426084 cancer prevention 0.384318 Complementary Therapies Editorial 0.435586 Cancer Information Specialist 0.399657 Drug Administration 0.382514 body 0.378493 Cancer Information Service 0.518118 PDQ cancer information 0.525476 Cancer Complementary 0.410407 CAM therapies 0.388339 Gerson’s therapy 0.456461 treatment clinical trials 0.381128 Gerson therapy reports 0.478587 National Cancer Institute 0.663474 clinical trials 0.562754 Dr. Gerson 0.569329 alternative medicine 0.46145 health care providers 0.421555 health care 0.444706 cancer information summary 0.471527 Max B. Gerson 0.46509 Gerson Research Organization 0.453179 alternative cancer therapies 0.404484	Federal Trade Commission 0.391653 National Institutes 0.385207 clinical trial 0.399404 National Center 0.376357 CAM cancer research 0.391227 new treatment 0.374685 breast cancer prevention 0.381892 patients 0.477683 cancer patients 0.443285 Cancer Care page 0.385186 latest published information 0.376378 key parts 0.39704 NCI’s PDQ 0.381863 PDQ summary 0.408051 Integrative Health 0.376266 NCI PDQ cancer 0.437412 cancer information database 0.407023 alternative therapies 0.430873 cancer information summaries 0.407395 Therapies Editorial Board 0.414248 cancer 0.692284 gerson therapy 0.948648 cancer information 0.545756	CLICK HERE
1685	National Cancer Institute	Html	en	Cannabis and Cannabinoids (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of Cannabis and cannabinoids in the treatment of cancer-related side effects, such as nausea and vomiting.	cannabinoid receptor CB2 0.721549 cancer cell proliferation 0.723514 opioid-treated cancer patients 0.721253 lung cancer 0.774703 testicular germ cell 0.736506 Cannabis trials 0.713054 endogenous cannabinoids 0.733591 bladder cancer 0.72104 clinical trials 0.71653 cannabinoid receptors 0.745589 advanced cancer patients 0.745457 CBD oromucosal spray 0.730536 cancer cell invasiveness 0.726743 Cancer Res 0.716198 cancer patients 0.801404 Investigational New Drug 0.714731 non-small cell lung 0.751006 effects 0.733811 colorectal cancer cell 0.727697 cancer chemotherapy 0.737056 cannabinoids 0.838589 et al. 0.767053 treatment 0.713465 study 0.761272 CBD 0.77215	United States 0.780596 Cannabis plant 0.728018 orally administered Cannabis 0.721336 Cancer Epidemiol Biomarkers 0.717008 cancer cell lines 0.803788 cannabinoid receptor 0.74565 THC 0.76674 Cannabis extract 0.739506 lung cancer chemotherapy 0.709535 cancer cell invasion 0.72445 breast cancer cell 0.789227 Cancer pain results 0.7118 cancer pain 0.721348 open-label extension study 0.709343 advanced cancer 0.748132 cell death 0.806928 Abstract 0.744659 cannabis 0.92504 germ cell tumors 0.735413 medicinal Cannabis 0.751597 cell lung cancer 0.728336 Cannabis species 0.726958 cancer 0.952946 Guidelines recommend cannabinoids 0.714742	CLICK HERE
2111	National Cancer Institute	Html	es	Exámenes de detección del cáncer de esófago (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de esófago.	PDQ Exámenes 0.728989 Physician Data Query 0.906997 libre uso 0.636785 prevención revisa 0.652274 información ayuda 0.682663 vías respiratorias 0.673206	carcinoma epidermoide 0.760269 National Cancer Institute 0.66546 cáncer.ampliar esofagoscopía 0.714851 siguientes riesgos 0.649549 siguientes sumarios 0.849506 Instituto Nacional 0.740034	CLICK HERE
3571	National Cancer Institute	Html	en	The ALCHEMIST Lung Cancer Trials	A collection of material about the ALCHEMIST lung cancer trials that will examine tumor tissue from patients with certain types of early-stage, completely resected non-small cell lung cancer for gene mutations in the EGFR and ALK genes, and assign patients with these gene mutations to treatment trials testing post-surgical use of drugs targeted against these mutations.	alchemist immunotherapy trial 0.735513 eligible patients 0.582681 ALK gene change 0.625433 lung cancer growth 0.56975 Enrichment Marker Identification 0.526695 early-stage ALK-positive NSCLC 0.619613 lung cancer 0.910812 ALK gene alteration 0.615379 ALCHEMIST ALK Trial 0.709714 clinical trials 0.620441 early-stage lung cancer 0.567191 immunotherapy drug nivolumab 0.565565 ALCHEMIST EGFR Trial 0.638344 EGFR mutations 0.573101 patients 0.888179 usual treatment 0.573579 ALCHEMIST ALK treatment 0.711658 early-stage NSCLC 0.852776 ALK rearrangement 0.750976 matching placebo pill 0.62375 immunotherapy trial testing 0.582385 treatment trial 0.824243 Adjuvant Lung Cancer 0.576364 ALCHEMIST treatment trial 0.778098	radiation therapy 0.64065 randomized clinical trials 0.539654 standard treatment regimen 0.538133 ALCHEMIST 0.810249 ALK gene 0.692713 EGFR mutation 0.52844 early-stage squamous-type NSCLC 0.617402 advanced lung cancer 0.620145 early-stage EGFR-positive NSCLC 0.626895 ALK alterations 0.567183 treatment clinical trials 0.541011 alk treatment trial 0.714543 following research question 0.711662 ALK genetic rearrangement 0.647794 ALCHEMIST trials test 0.647386 lung cancer patients 0.596702 ALCHEMIST studies 0.5468 patient handout 0.660811 early-stage NSCLC patients 0.669994 ALCHEMIST EGFR treatment 0.639285 ALCHEMIST Screening Trial 0.627147 Immunotherapy Treatment Trial 0.587466 cell lung cancer 0.573239 ALCHEMIST trials 0.691377	CLICK HERE
16793	National Cancer Institute	Html	en	Financial Toxicity (Financial Distress) and Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the risk of experiencing financial difficulty during cancer treatment.	cancer treatment 0.560892 Younger cancer patients 0.529926 cancer prevention 0.471224 health insurance 0.682664 financial problems 0.494439 Cancer Information Service 0.481412 PDQ cancer information 0.587068 higher out-of-pocket spending 0.47295 private health insurance 0.465224 prescription drugs 0.484017 treatment clinical trials 0.459002 National Cancer Institute 0.544987 cancer costs 0.462877 clinical trials 0.510144 high out-of-pocket costs 0.468181 higher out-of-pocket costs 0.473438 cancer information summary 0.537897 clinical trial 0.468454 cancer care 0.516942 higher risk 0.49888 new treatment 0.460656 breast cancer prevention 0.469712 ongoing cancer treatment 0.492965	PDQ summaries 0.458846 cancer patients 0.660406 Cancer Care page 0.476388 latest published information 0.457905 terms financial toxicity 0.527252 cancer diagnosis 0.478766 public health insurance 0.493734 medical care 0.477841 NCI’s PDQ 0.458764 PDQ summary 0.479746 PDQ Adult Treatment 0.486617 NCI PDQ cancer 0.505611 out-of-pocket costs 0.569773 employment-based health insurance 0.468504 financial toxicity 0.965386 PDQ Financial Toxicity 0.536789 Treatment Editorial Board 0.495414 cancer information summaries 0.485053 comprehensive cancer information 0.485328 randomized clinical trials 0.460338 cancer 0.830208 Cancer survivors 0.518214 older cancer patients 0.493956	CLICK HERE
16823	National Cancer Institute	Html	en	Cancer Moonshot℠ Funding Opportunities Resources	Funding opportunities that address the goals of the Blue Ribbon Panel are available. Learn more about these FOAs and pre-application webinars.	childhood cancers 0.82856 Pre-Application Webinar 0.778347 novel analytic methods 0.732759 multi-institutional research centers 0.785637 general research community 0.764628 Cancer Moonshot-related research 0.831068 fusion-driven childhood cancers 0.777954 fusion oncoproteins 0.905172 future study design 0.733286 specific immune cells 0.77412 NCI programs 0.757592 Data Coordinating Center 0.787709 Pediatric Immunotherapy Discovery 0.777846 hereditary cancer syndromes 0.74689 major human cancers 0.800396 FOA 0.828079 low mutation burden 0.742617 anti-tumor immune responses 0.776471 Cancer Immunotherapy Consortium 0.806729 Data Registry 0.754495 human tumor atlases 0.783474 comprehensive research plan 0.779129 implementation strategies 0.734791 Childhood Cancers Consortium 0.773471 potential therapeutic value 0.731056	NCI Precision Medicine 0.75058 tumor immune microenvironment 0.832442 research centers 0.82836 PRO-CTCAE data 0.744037 extramural research communities 0.782614 multi-level implementation strategies 0.733334 upcoming scientific opportunities 0.76054 integrated symptom assessment 0.732627 immune cell function 0.77759 data management 0.771879 select fusion oncoproteins 0.75065 immunosuppressive tumor 0.729662 implementation science applications 0.742692 future cancer research 0.790904 ACCSIS FOA 0.755625 Blue Ribbon Panel 0.748367 IMPACT FOA 0.770073 Tumor Atlas Network 0.790652 multiple clinical practices 0.750243 clinical trial data 0.780778 Human Tumor Atlas 0.855426 cancer clinical trials 0.773656 biological mechanisms 0.745506 comprehensive clinical data 0.778703	CLICK HERE